TY - JOUR
T1 - Targeted drug delivery in cervical cancer
T2 - Current perspectives
AU - Ghosh, Supriti
AU - Jayaram, Pradyumna
AU - Kabekkodu, Shama Prasada
AU - Satyamoorthy, Kapaettu
N1 - Funding Information:
The authors thank Department of Biotechnology ( DBT ), Government of India, Science and Engineering Research Board ( SERB ), Department of Science and Technology ( DST ), Government of India and TIFAC core in Pharmacogenomics for financial support and Manipal Academy of Higher Education (MAHE) for infrastructure support. We would like to thank DST-INSPIRE fellowship (IF150647), Government of India for providing financial assistance to SG and ICMR-Senior Research fellowship, Government of India (Reference ID -BMI/11(107)/2020), for providing financial assistance to PJ.
Funding Information:
The National University of Singapore supports both drug developers and regulatory agencies by characterisation and qualitative analysis of nanomedicines from clinical datasets (Allan et al., 2021).The authors thank Department of Biotechnology (DBT), Government of India, Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Government of India and TIFAC core in Pharmacogenomics for financial support and Manipal Academy of Higher Education (MAHE) for infrastructure support. We would like to thank DST-INSPIRE fellowship (IF150647), Government of India for providing financial assistance to SG and ICMR-Senior Research fellowship, Government of India (Reference ID -BMI/11(107)/2020), for providing financial assistance to PJ.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Cervical cancer is preventable yet one of the most prevalent cancers among women around the globe. Though regular screening has resulted in the decline in incidence, the disease claims a high number of lives every year, especially in the developing countries. Owing to rather aggressive and non-specific nature of the conventional chemotherapeutics, there is a growing need for newer treatment modalities. The advent of nanotechnology has assisted in this through the use of nanocarriers for targeted drug delivery. A number of nanocarriers are continuously being developed and studied for their application in drug delivery. The present review summarises the different drug delivery approaches and nanocarriers that can be useful, their advantages and limitation.
AB - Cervical cancer is preventable yet one of the most prevalent cancers among women around the globe. Though regular screening has resulted in the decline in incidence, the disease claims a high number of lives every year, especially in the developing countries. Owing to rather aggressive and non-specific nature of the conventional chemotherapeutics, there is a growing need for newer treatment modalities. The advent of nanotechnology has assisted in this through the use of nanocarriers for targeted drug delivery. A number of nanocarriers are continuously being developed and studied for their application in drug delivery. The present review summarises the different drug delivery approaches and nanocarriers that can be useful, their advantages and limitation.
UR - http://www.scopus.com/inward/record.url?scp=85122639004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122639004&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2022.174751
DO - 10.1016/j.ejphar.2022.174751
M3 - Review article
AN - SCOPUS:85122639004
SN - 0014-2999
VL - 917
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
M1 - 174751
ER -
